Key Insights

Highlights

Success Rate

86% trial completion

Published Results

44 trials with published results (31%)

Research Maturity

81 completed trials (57% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 29/100

Termination Rate

9.2%

13 terminated out of 141 trials

Success Rate

86.2%

-0.3% vs benchmark

Late-Stage Pipeline

26%

36 trials in Phase 3/4

Results Transparency

54%

44 of 81 completed with results

Key Signals

44 with results86% success13 terminated

Data Visualizations

Phase Distribution

100Total
Not Applicable (25)
Early P 1 (3)
P 1 (16)
P 2 (20)
P 3 (19)
P 4 (17)

Trial Status

Completed81
Unknown27
Terminated13
Recruiting10
Not Yet Recruiting4
Active Not Recruiting3

Trial Success Rate

86.2%

Benchmark: 86.5%

Based on 81 completed trials

Clinical Trials (141)

Showing 20 of 20 trials
NCT03680794Not ApplicableRecruiting

Soluble Cluster of Differentiation 160 (sCD160) in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies

NCT07456826Phase 4Recruiting

Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections

NCT01496625Recruiting

National Eye Institute Biorepository for Retinal Diseases

NCT07501052Phase 2Not Yet Recruiting

Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy

NCT07481500Not ApplicableNot Yet Recruiting

Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Trial of Pain, Procedure Time, Patient Satisfaction, and Safety

NCT05476926Active Not Recruiting

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

NCT07318428Not ApplicableEnrolling By Invitation

AI-Assisted Detection of Posterior Segment Diseases: DR, AMD, RVO, and Glaucoma

NCT04505618Not ApplicableRecruiting

Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease

NCT06439576Recruiting

Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)

NCT04008121Early Phase 1Recruiting

Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

NCT07298174Not Yet Recruiting

Wide Field OCTA in Ocular Diseases

NCT07259928Phase 2Recruiting

Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion

NCT07106268Active Not RecruitingPrimary

Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema

NCT07002372Not ApplicableRecruiting

Effect of Video Viewing on Intravitreal Injection Experience

NCT05099094Early Phase 1Active Not Recruiting

VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases

NCT04635800Phase 1Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients

NCT04707625Phase 4TerminatedPrimary

Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment

NCT05003258Not ApplicableCompleted

Functional and Anatomical Outcomes of Dexamethasone Intra-vitreal Implant in Patients with Resistant Macular Edema Secondary to Retinal Vein Occlusion After Intravitreal Anti-VEGF Injection

NCT06757595CompletedPrimary

Retrospective Analysis of the Clinical Characteristics of Retinal Vein Occlusion

NCT06176963Phase 2Completed

A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO

Scroll to load more

Research Network

Activity Timeline